Low Growth Hormone May Raise CVD Risk

BY JEFF EVANS

WASHINGTON — A low level of growth hormone in obese adults is independently associated with increased carotid intima media thickness, which may translate into an elevated risk of cardiovascular disease and a severe metabolic phenotype, according to the results of a prospective, observational study.

Building on evidence gathered from

previous studies of growth hormone (GH) levels in obese men and women, Dr. Hideo Makimura and his colleagues in the neuroendocrine unit and program in nutritional metabolism at Massachusetts General Hospital, Boston, analyzed stimulated GH secretion levels and other cardiometabolic risk factors in 102 lean and obese individuals.

Taken together, these data suggest [that] strategies to increase growth hormone secretion may improve cardiovascular risk in obesity," Dr. Makimura said during the presentation of his study at the annual meeting of the Endocrine Society.

Studies including frequent blood sampling of GH have shown 75% less 24hour GH secretion in obese men, compared with age-matched lean men. Other studies have found that 64% of obese men have a peak stimulated GH level of less than 9 mcg/L in standardized GH-

Register Now!

releasing hormone-arginine testing, whereas less than 1% of lean men have such a level. Reduced GH has been associated with an increase in carotid intima media thickness (cIMT), a measure of atherosclerosis, in overweight and obese

Dr. Makimura and his associates followed 33 lean individuals, 55 obese individuals who had sufficient growth hormone, and 14 obese individuals who were deficient in growth hormone (peak stimulation GH level of 4.2 mcg/L or less). The groups had mean ages in the low to mid 40s. The participants were matched for age, sex, race, tobacco use, and blood pressure. The obese groups also were matched for body mass index and visceral adiposity.

GH-deficient obese participants had a greater mean carotid intima media thickness than did lean participants, but there was no significant difference in cIMT between the obese groups.

Lean individuals had a mean BMI of 22.5 kg/m², whereas GH-sufficient obese participants had a mean BMI of 37.2 kg/m² and GH-deficient obese participants had a mean BMI of 40.7 kg/m^2 .

In a univariate analysis, peak GH negatively correlated with cIMT. GH-deficient obese participants had a greater mean cIMT than did lean participants, but there was no significant difference in cIMT between the obese groups.

The researchers obtained the same results when they used more liberal cutoffs, defining GH deficiency as peak stimulated GH secretion concentrations of less than 5 mcg/L or less than 9 mcg/L.

Dr. Makimura and his associates found in univariate analyses that peak stimulated GH also was negatively correlated with the amount of visceral adipose tissue, as well as with LDL cholesterol, triglycerides, C-reactive protein, tumor necrosis factor-alpha, and measures of insulin sensitivity.

The association between peak stimulated GH and cIMT remained significant in separate multivariate regression analyses that controlled for demographic factors, traditional cardiovascular disease risk factors (tobacco use, systolic blood pressure, and levels of cholesterol and fasting blood glucose), metabolic variables (visceral adipose tissue, BMI, HDL and LDL cholesterol, triglycerides, fasting glucose, and fasting insulin), or inflammatory markers (C-reactive protein, adiponectin, and tumor necrosis factor-alpha).

Dr. Makimura concluded that these GH-related cardiometabolic risk factors may mediate the association between reduced GH secretion in obesity and increased cIMT.

The study was funded by grants from the National Institutes of Health. Dr. Makimura disclosed no relevant conflicts of interest.

Boston University School of Medicine

Pediatric News / Family Practice News

JOINTLY SPONSOR

Pediatric Infectious Diseases in the Headlines

A Continuing Medical Education Conference

October 24 – 25, 2009 Royal Sonesta Hotel, Cambridge, MA

Topic Highlights:

- What Is The Diagnosis? with James H. Brien, DO
- Influenza Challenges: Diagnosis, Treatment, Resistance, and Immunization
- CaMRSA Diagnosis, Treatment, and Prevention
- Otitis Media Is There Consensus About Treatment and Prevention?
- The Child With Stridor Diagnosis and Management
- EBV: Diagnosis, Complications, and Complex Cases
- Impact of the Rotavirus Vaccine on Rotavirus Disease
- Malaria: Recognition and Management
- HPV Vaccine: What Have We Learned?
- Next Steps in Preventing Meningococcal Disease in Children Next Generation Pneumococcal Vaccines
- Does Probiotic Use Limit Certain Infections?
- New Challenges for Travelers
- · Hectic Fevers in the First Year of Life
- Vaccine Safety STD Guidelines



Target Audience: This conference is designed for pediatricians, family practitioners, general practitioners, nurse practitioners, residents, and allied health professionals.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and *Pediatric News/Family Practice News*. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this educational activity for a maximum of 12.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Continuing Medical Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Educational Objectives: Through participation in case discussions, small group workshops, and attendance at lectures, participants will be able to:

- Apply evidence-based practices concerning immunization across the pediatric life-span
- · Identify less commonly seen travel-acquired diseases
- · Improve identification and treatment of various pediatric infectious diseases

Course Directors

Jerome O. Klein, MD

Visiting Physician, Boston Medical Center

Stephen I. Pelton, MD

Professor of Pediatrics, Boston University School of Medicine Director, Section of Pediatric Infectious Diseases, Boston Medical Center

Guest Faculty

James H. Brien, DO

iatric Infectious Diseases Section Associate Professor and Head, Pediatric Infe Scott White Memorial Hospital Texas A&M University College of Medicine

Boston University School of Medicine / Boston Medical Center Faculty

Elizabeth D. Barnett, MD

Associate Professor of Pediatrics
Director, International Clinic, Section of Pediatric Infectious Diseases

Howard Bauchner, MD

Professor of Pediatrics and Public Heal Director, Division of General Pediatrics

Ellen R. Cooper, MD

Professor of Pediatrics Medical Director, Diagnostic Evaluation Unit, Section of Pediatric Infectious Dis

Marisol Figueira, MD

Kenneth Grundfast, MD

Department of Otolaryngology – Head and Neck Surgery or and Chairman, Otolaryngology – Head and Neck Surgery

Katherine Hsu, MD, MPH

Carole H. Moloney, RN, MSN, CPNP

Colin D. Marchant, MD

Vishakha Sabharwal, MD

Sandra K. Schumacher, MD, MPH

To register, please contact:

Boston University School of Medicine Continuing Medical Education

72 East Concord Street, A305 Boston, MA, 02118

Phone: (617) 638-4605 Toll-free: (800) 688-2475 Fax: (617) 638-4905 E-mail: cme@bu.edu

Website: www.bu.edu/cme